These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 8884164)

  • 1. Drug-induced disorders of glucose metabolism. Mechanisms and management.
    Chan JC; Cockram CS; Critchley JA
    Drug Saf; 1996 Aug; 15(2):135-57. PubMed ID: 8884164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ
    Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of antidiabetic medications in overdose.
    Spiller HA
    Drug Saf; 1998 Nov; 19(5):411-24. PubMed ID: 9825953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.
    Scheen AJ
    Drug Saf; 2005 Jul; 28(7):601-631. PubMed ID: 27722966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative tolerability profiles of oral antidiabetic agents.
    Krentz AJ; Ferner RE; Bailey CJ
    Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihyperglycaemic agents. Drug interactions of clinical importance.
    Scheen AJ; Lefèbvre PJ
    Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimethoprim-sulfamethoxazole-associated severe hypoglycaemia: a sulfonylurea-like effect.
    Nunnari G; Celesia BM; Bellissimo F; Tosto S; La Rocca M; Giarratana F; Benanti F; Caltabiano E; Russo R; Cacopardo B
    Eur Rev Med Pharmacol Sci; 2010 Dec; 14(12):1015-8. PubMed ID: 21375132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention.
    Chelliah A; Burge MR
    Drugs Aging; 2004; 21(8):511-30. PubMed ID: 15182216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of activated glucose counterregulation on insulin requirements in insulin-dependent diabetes mellitus.
    Bolli GB; Perriello G
    Horm Metab Res Suppl; 1990; 24():87-96. PubMed ID: 2272633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.
    Rizza RA; Cryer PE; Gerich JE
    J Clin Invest; 1979 Jul; 64(1):62-71. PubMed ID: 36413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated Type 2 diabetes.
    Choudhary P; Lonnen K; Emery CJ; MacDonald IA; MacLeod KM; Amiel SA; Heller SR
    Diabet Med; 2009 Jul; 26(7):665-72. PubMed ID: 19573114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
    Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M
    Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dangerous and common drug interactions in patients with diabetes mellitus.
    White JR; Campbell RK
    Endocrinol Metab Clin North Am; 2000 Dec; 29(4):789-802. PubMed ID: 11149162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
    Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
    Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide.
    Lheureux PE; Zahir S; Penaloza A; Gris M
    Crit Care; 2005; 9(6):543-9. PubMed ID: 16356235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.
    Gavin JR; Kubin R; Choudhri S; Kubitza D; Himmel H; Gross R; Meyer JM
    Drug Saf; 2004; 27(9):671-86. PubMed ID: 15230648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unawareness of hypoglycaemia and inadequate hypoglycaemic counterregulation: no causal relation with diabetic autonomic neuropathy.
    Ryder RE; Owens DR; Hayes TM; Ghatei MA; Bloom SR
    BMJ; 1990 Oct; 301(6755):783-7. PubMed ID: 2224265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [How I treat...severe hypoglycemia in a diabetic patient].
    Radermecker RP; Philips JC; Scheen AJ
    Rev Med Liege; 2003 Mar; 58(3):119-22. PubMed ID: 12723504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.